<![CDATA[Genmab — Februar 2018]]>God morgen. 🙂

]]>https://dev.proinvestor.com/forum/topic/451515/genmab-februar-2018RSS for NodeSun, 14 Jun 2026 02:46:12 GMTThu, 01 Feb 2018 05:18:28 GMT60<![CDATA[Reply to Genmab — Februar 2018 on Wed, 28 Feb 2018 21:47:15 GMT]]>Ved nærmere eftersyn af skemaet på side 100 af 124 i årsregnskabet, kan jeg se, at jeg alligevel har ret i den 7 årige aldersgrænse for warrants - den er bare ændret, så de ældste fra før 2010 eller 11 har haft en grænse på 10 år.

]]>https://dev.proinvestor.com/forum/post/10174272https://dev.proinvestor.com/forum/post/10174272Wed, 28 Feb 2018 21:47:15 GMT<![CDATA[Reply to Genmab — Februar 2018 on Wed, 28 Feb 2018 21:32:04 GMT]]>Hej (også)Pensionist - Jeg overraskes skam ikke, vi ved,at de kommer. Men det er da glædeligt, at der fremover vil blive færre, da de jo udvander værdien af øvrige aktier. Jeg har også flere gange udtrykt, at de aktionærer, der var misundelige over, at ansatte i Genmab fik billige aktier, de skulle jo bare selv have købt, dengang kursen var dernede.

]]>https://dev.proinvestor.com/forum/post/10174268https://dev.proinvestor.com/forum/post/10174268Wed, 28 Feb 2018 21:32:04 GMT<![CDATA[Reply to Genmab — Februar 2018 on Wed, 28 Feb 2018 21:31:49 GMT]]>Warrents kan ikke overraske nogen de kommer i en lind strøm.

]]>https://dev.proinvestor.com/forum/post/10174273https://dev.proinvestor.com/forum/post/10174273Wed, 28 Feb 2018 21:31:49 GMT<![CDATA[Reply to Genmab — Februar 2018 on Wed, 28 Feb 2018 21:22:30 GMT]]>Min påstand om at warrants udløber efter 7 år holder vist ikke. De poster, der er indløst til henhv. kurs 234 - 246 - 254 og 272 er udstedt helt tilbage i 2008.

]]>https://dev.proinvestor.com/forum/post/10174269https://dev.proinvestor.com/forum/post/10174269Wed, 28 Feb 2018 21:22:30 GMT<![CDATA[Reply to Genmab — Februar 2018 on Wed, 28 Feb 2018 18:58:40 GMT]]>1,5 mln warrants outstanding. Down from 2,2 mln last year.

]]>https://dev.proinvestor.com/forum/post/10174271https://dev.proinvestor.com/forum/post/10174271Wed, 28 Feb 2018 18:58:40 GMT<![CDATA[Reply to Genmab — Februar 2018 on Wed, 28 Feb 2018 18:47:14 GMT]]>No - I didn´t see that, but I will find it. Thanks.

]]>https://dev.proinvestor.com/forum/post/10174270https://dev.proinvestor.com/forum/post/10174270Wed, 28 Feb 2018 18:47:14 GMT<![CDATA[Reply to Genmab — Februar 2018 on Wed, 28 Feb 2018 18:41:16 GMT]]>@ bikube ; you may have seen it already, but the annual report had a really good overview of outstanding warrants, split out in exercise price and time remaining

]]>https://dev.proinvestor.com/forum/post/10174266https://dev.proinvestor.com/forum/post/10174266Wed, 28 Feb 2018 18:41:16 GMT<![CDATA[Reply to Genmab — Februar 2018 on Wed, 28 Feb 2018 18:28:58 GMT]]>En skam Gen er ved at blive voksen. 🙂

]]>https://dev.proinvestor.com/forum/post/10174267https://dev.proinvestor.com/forum/post/10174267Wed, 28 Feb 2018 18:28:58 GMT<![CDATA[Reply to Genmab — Februar 2018 on Wed, 28 Feb 2018 18:21:34 GMT]]>Det forløb viser nok med al tydelighed, at Big Pharma skal vente til data er sikre nok med at købe de små biotech

]]>https://dev.proinvestor.com/forum/post/10174265https://dev.proinvestor.com/forum/post/10174265Wed, 28 Feb 2018 18:21:34 GMT<![CDATA[Reply to Genmab — Februar 2018 on Wed, 28 Feb 2018 18:20:06 GMT]]>CELG startede i 2014 med en licensaftale med upfront på ca $700 mln. Data rullede ind i 2015 og medio 2015 købte de Receptos og midlet ozanimod for $7,2 bn http://ir.celgene.com/releasedetail.cfm?ReleaseID=922090 Nu da fda ikke synes om bivirkningerne kan det hele være tabt.

]]>https://dev.proinvestor.com/forum/post/10174262https://dev.proinvestor.com/forum/post/10174262Wed, 28 Feb 2018 18:20:06 GMT<![CDATA[Reply to Genmab — Februar 2018 on Wed, 28 Feb 2018 18:05:40 GMT]]>Gennemsnit pris for de nye aktier 280 dkkr. Der er stadig nogl tilbage til under 100 kr., men de skal jo indløses inden 7 år fra udstedelsen, så det får da en ende med de helt billige.

]]>https://dev.proinvestor.com/forum/post/10174263https://dev.proinvestor.com/forum/post/10174263Wed, 28 Feb 2018 18:05:40 GMT<![CDATA[Reply to Genmab — Februar 2018 on Wed, 28 Feb 2018 18:02:14 GMT]]>
Access denied | www.fiercebiotech.com used Cloudflare to restrict access | www.fiercebiotech.com | Cloudflare

favicon

(www.fiercebiotech.com)

]]>https://dev.proinvestor.com/forum/post/10174261https://dev.proinvestor.com/forum/post/10174261Wed, 28 Feb 2018 18:02:14 GMT<![CDATA[Reply to Genmab — Februar 2018 on Wed, 28 Feb 2018 17:59:34 GMT]]>E L's link 9:47 is the reason why Celg drops 8% https://www.marketwatch.com/story/celgene-shares-drop-6-after-blunder-with-high-profile-drug-2018-02-28

]]>https://dev.proinvestor.com/forum/post/10174259https://dev.proinvestor.com/forum/post/10174259Wed, 28 Feb 2018 17:59:34 GMT<![CDATA[Reply to Genmab — Februar 2018 on Wed, 28 Feb 2018 17:58:31 GMT]]>E L

]]>https://dev.proinvestor.com/forum/post/10174264https://dev.proinvestor.com/forum/post/10174264Wed, 28 Feb 2018 17:58:31 GMT<![CDATA[Reply to Genmab — Februar 2018 on Wed, 28 Feb 2018 17:55:21 GMT]]>Det er ca 3 gange så mange warrants denne gang som de sidste 2 gange, men langt færre end i juni.

]]>https://dev.proinvestor.com/forum/post/10174258https://dev.proinvestor.com/forum/post/10174258Wed, 28 Feb 2018 17:55:21 GMT<![CDATA[Reply to Genmab — Februar 2018 on Wed, 28 Feb 2018 17:33:14 GMT]]>GMXAY med ca 200K eller ca 100K aktier. Markant omsætningsstigning de seneste dage i US.

]]>https://dev.proinvestor.com/forum/post/10174256https://dev.proinvestor.com/forum/post/10174256Wed, 28 Feb 2018 17:33:14 GMT<![CDATA[Reply to Genmab — Februar 2018 on Wed, 28 Feb 2018 17:02:10 GMT]]>Proceeds to the company are approximately DKK 18.3 million. The increase
corresponds to approx. 0.11% of the companys share capital.

]]>https://dev.proinvestor.com/forum/post/10174257https://dev.proinvestor.com/forum/post/10174257Wed, 28 Feb 2018 17:02:10 GMT<![CDATA[Reply to Genmab — Februar 2018 on Wed, 28 Feb 2018 17:01:40 GMT]]>
  • 220 shares at DKK 40.41,
    -- 1,800 shares at DKK 68.65,
    -- 3,625 shares at DKK 80.55,
    -- 350 shares at DKK 210,
    -- 250 shares at DKK 220.40,
    -- 18,813 shares at DKK 225.90,
    -- 200 shares at DKK 231.50,
    -- 1,250 shares at DKK 234,
    -- 1,250 shares at DKK 246,
    -- 21,535 shares at DKK 254,
    -- 6,850 shares at DKK 272,
    -- 5,188 shares at DKK 337.40,
    -- 88 shares at DKK 466.20, and
    -- 4,000 shares at DKK 939.50.
    • ]]>    https://dev.proinvestor.com/forum/post/10174253https://dev.proinvestor.com/forum/post/10174253Wed, 28 Feb 2018 17:01:40 GMT    <![CDATA[Reply to Genmab — Februar 2018 on Wed, 28 Feb 2018 16:59:28 GMT]]>Ja, men 6 gange om året bliver til noget. Næsten 800.000 nye aktier alene sidste år. Ikke at jeg orker at hidse mig voldsomt op over det, men alligevel....

    ]]>    https://dev.proinvestor.com/forum/post/10174254https://dev.proinvestor.com/forum/post/10174254Wed, 28 Feb 2018 16:59:28 GMT    <![CDATA[Reply to Genmab — Februar 2018 on Wed, 28 Feb 2018 16:38:07 GMT]]>0,11 pct 😉

    ]]>    https://dev.proinvestor.com/forum/post/10174260https://dev.proinvestor.com/forum/post/10174260Wed, 28 Feb 2018 16:38:07 GMT    <![CDATA[Reply to Genmab — Februar 2018 on Wed, 28 Feb 2018 16:35:45 GMT]]>65,419stk

    ]]>    https://dev.proinvestor.com/forum/post/10174250https://dev.proinvestor.com/forum/post/10174250Wed, 28 Feb 2018 16:35:45 GMT    <![CDATA[Reply to Genmab — Februar 2018 on Wed, 28 Feb 2018 16:35:13 GMT]]>så kom warrents

    ]]>    https://dev.proinvestor.com/forum/post/10174248https://dev.proinvestor.com/forum/post/10174248Wed, 28 Feb 2018 16:35:13 GMT    <![CDATA[Reply to Genmab — Februar 2018 on Wed, 28 Feb 2018 16:12:25 GMT]]>Xencor. https://www.fiercebiotech.com/cro/xencor-extends-collaboration-selexis-to-advance-bispecific-antibody-programs?mkt_tok=eyJpIjoiWm1VelptRmpaR0kxTlRkbCIsInQiOiIwdTFsOHlcL0h5QVdCeEx1R3Vvd1N4K1dGVXFrYlRXS1oySERTXC9OZmRSbHM5RlQ0bFV3cTJLc1lXTUpHalNKUVNiMllkVmZoNzlMWVBiSytoenIxNlVcL0pUN01CXC85ZjRnS1ZpNFp4c1FZdnZiVlFCd0Mwd3lkVDZpME1nM2hhZ0YifQ%3D%3D&mrkid=41140432

    ]]>    https://dev.proinvestor.com/forum/post/10174251https://dev.proinvestor.com/forum/post/10174251Wed, 28 Feb 2018 16:12:25 GMT    <![CDATA[Reply to Genmab — Februar 2018 on Wed, 28 Feb 2018 15:59:20 GMT]]>Xencor stiger pænt - de har som nævnt før noget action i deres bispecifikke pipeline

    ]]>    https://dev.proinvestor.com/forum/post/10174252https://dev.proinvestor.com/forum/post/10174252Wed, 28 Feb 2018 15:59:20 GMT